Makary Introduces One-Day Inspections, Touts Agency’s Embrace Of Bold Ideas
During a fireside chat hosted by the Food and Drug Law Institute on Wednesday, FDA Commissioner Marty Makary noted several agency initiatives, including one-day inspections, hiring more staff, and speeding up approvals.
Medtech Insight - May 6, 2026

Semaglutide Scaling Continues In Canada With Apotex Approval
Already the first G7 nation to move past the brand name for Ozempic, Canada has announced another generic approval, this time for Apotex.
Generics Bulletin - May 6, 2026

How Sun Pharma’s Organon Deal Unlocks China’s ‘Hidden Optionality’ And New Markets
The $11.75bn Organon acquisition gives Sun Pharma a platform it has lacked: scale in China, a global footprint for in-licensing and new market footholds across 10 countries. In an interview with Scrip, MD Kirti Ganorkar sets out how Sun plans to move forward.
Scrip - May 6, 2026

Xbrane Looks At Its Opdivo Biosimilar Partner Intas For Cash
A revised Intas deal on nivolumab buys Xbrane some financial breathing room, but the Swedish firm still needs to cut costs on its only revenue-generating product while racing to stay relevant in a crowded eye care market.
Generics Bulletin - May 6, 2026

Bayer Beefs Up In Ophthalmology With Perfuse Buyout
Bayer is expanding its ophthalmology pipeline beyond Eylea with a deal for Perfuse Therapeutics that could be worth $2.45bn.
Scrip - May 6, 2026

Roche Still Supports Switzerland But Signs Of Strain Showing
CEO Thomas Schinecker talks taxes, pricing and pharma’s contribution to society at Swiss Biotech Day.
Scrip - May 6, 2026

Novo Is Winning In Early Obesity Pill Market But Prices Will Never Be The Same
The Danish company has achieved the best ever obesity launch thanks to consumer enthusiasm for a cut price oral Wegovy
Scrip - May 6, 2026

Could Do Better: MedTech Europe Supports MDR/IVDR Revision Plan But Wants More
MedTech Europe voiced support for the direction of the European Commission’s MDR/IVDR proposed reform, but called for further changes to ensure workable outcomes for industry.
Medtech Insight - May 6, 2026

BioNTech To Cut 1,860 Jobs As Part Of Post-COVID Restructuring
BioNTech is restructuring parts of its pandemic-era manufacturing network and redirecting capital toward late-stage oncology programs as the company prepares for future cancer drug launches amid declining COVID-19 vaccine revenues.
Scrip - May 6, 2026

Two Speeds: The Solid Tumor Markets Racing Ahead And The Ones Left Behind
In this article, the second of the oncology therapeutic review series, In Vivo examines the major solid tumor cancer types driving the oncology market.
In Vivo - May 6, 2026

GSK Bolsters Downstream Obesity Strategy By Gaining SiranBio’s siRNA Drug
GSK is likely to ride the fresh deal to up its game in metabolic dysfunction-associated steatohepatitis (MASH), while still staying out of the increasingly crowded weight-loss space.
Scrip - May 6, 2026

Biomed 2026: From Device To Healthtech Via Software, Data And AI
Peregrine Ventures’ managing general partner Eyal Lifschitz gave a broad-brush picture of the themes investors, founders and innovators can expect to discuss on a panel session he will co-host at Biomed Israel 2026.
In Vivo - May 6, 2026

Church & Dwight Sees Inflation Pressuring Consumers, But Higher Costs Could Trigger Pricing
“We have no plans to try to price through” a $25m to $30m headwind from costs and inflation, says CEO Richard Dierker. But it grows to $50 million to $150 million, “who knows where it stops, then you have to solve a different problem with different solutions.”
HBW Insight - May 6, 2026